3 research outputs found
νμ μΈν¬ μ λ μΈν°λ£¨ν¨-23μ μν μ μ²μ± λ¦Όνꡬ μΈν¬ 1νμμ 3νμΌλ‘μ λ³νμ΄ μ’ μ μ±μ₯μ λ―ΈμΉλ μν₯ μ°κ΅¬
νμλ
Όλ¬Έ(λ°μ¬)--μμΈλνκ΅ λνμ :μκ³Όλν μνκ³Ό,2019. 8. κΉμ§μ.Due to the recent success of immunotherapy in non-small cell lung cancer (NSCLC) patients, there has been a growing interest in the role of immune cells in tumor microenvironment (TME). Innate lymphoid cell (ILC) is one kind of immune subsets which might contribute to the TME yet relatively unexplored. ILC has three subsets classified according to their transcription factor and cytokine expression, however, the plasticity between ILC subsets has been reported in the inflammatory bowel disease by in vitro experiments. Up to now, the effect of ILC subsets and their plasticity with changes in cytokines on TME has not been fully investigated. This study aimed to reveal the role of ILC plasticity and significance for potential therapeutic target in human lung TME.
ILC subsets and cytokine expression profiles were evaluated in 80 cases of NSCLC each consisting of 40 squamous cell carcinoma (SqCC) and 40 adenocarcinoma (ADC) with matched normal lung tissue, which were freshly collected in Seoul National University Hospital. Experimental conversion of ILC1 into ILC3 under co-culture with lung cancer cells was explored. The contribution of IL-23 on tumor growth and regulation of immune components in TME was investigated using in vivo mouse tumor model. Verification and prognostic effects of converted ILC3 and related pathways were evaluated by tissue microarray from retrospective cohort composed of 875 lung cancer patients.
As a result, IL-17RA expression on tumor cells and IL-17A expression on immune cells from TME were significantly higher in SqCC than ADC, which suggests that IL-17 has pro-tumoral effects in pulmonary SqCC. Among IL-17+ cells, the percentages of ILCs were higher in SqCC than ADCs, and also ILC3s were more frequent that ILC1s in SqCC in contrast to ADC or normal lung tissue. Among cytokines which were involved in plasticity of ILC1 and ILC3, only IL-23 mRNA or protein expression from tumor cells was significantly correlated with the number of ILC1 and ILC3. And the percentage of ILC3 was associated with IL-23 expression in tumor cells but not immune cells.
Based on these findings, it was suggested that the conversion of ILC1 from ILC3 in TME could be caused by IL-23 expression from tumor cells. The polarization of ILC1 into ILC3 was observed in experiment of in vitro co-culture model using sorted-ILC1 or total ILCs and SqCC which expresses high level of IL-23, but not in co-culture of sorted ILC1 or total ILCs and ADCs. In in vivo murine tumor model, tumor growth was dependent on IL-23 expression from tumor cells via IL-17 from converted ILC3 from ILC1.
In retrospective cohort using immunohistochemistry on TMA, the numbers of CD3-RORΞ³t+ ILC3, IL-17 expression level, and IL-23- or IL-17RA-expressing tumor cells were more frequently observed in SqCC. These factors were also associated with short survival of patients with SqCC but not ADC.
In conclusion, these results indicate that IL-23 produced by tumor cells drives differentiation ILC1 toward ILC3 and the interaction of IL-17 expression from ILC3 and IL-17R on tumor cells promotes tumor proliferation. Therefore, the IL-23 β ILC3 β IL-17 axis affects to poor prognosis in lung cancer patients, this axis may suggest potential immunotherapy targets for patients with IL-23-producing lung cancers.μ΅κ·Ό PD-1μ λΉλ‘―ν λ©΄μ μΉλ£κ° νμμκ² μ’μ λ°μμ 보μ΄λ©΄μ μ’
μ λ―ΈμΈνκ²½μ μ‘΄μ¬νλ λ©΄μμΈν¬μ λν μ΄ν΄κ° κ·Έ μ΄λ λλ³΄λ€ μ€μν΄μ§κ³ μλ€. μ μ²μ± λ¦Όνꡬ μΈν¬λ μ μ²μ± λ©΄μ μΈν¬μ κ°κΉμ§λ§ λμ TμΈν¬μ μμνλ μν μ λ΄λΉνλ νΉμ§μ κ°μ§ λΉκ΅μ μ΅κ·Όμ λ°νμ§ μΈν¬κ΅°μ΄λ€. μ μ²μ± λ¦Όνꡬ μΈν¬λ κ° λ°ννλ μ μ¬μΈμ λ° λΆλΉνλ μ¬μ΄ν μΉ΄μΈμ ν΅ν΄ 3κ°μ§ μνμΌλ‘ λλλ€. μ μ²μ± λ¦Όνꡬ μΈν¬ μν κ° νμ§ μ νμ λμ₯μΌ μ€ν λͺ¨λΈμμ λ³΄κ³ λ λ° μμΌλ μ’
μμμλ μμ§κΉμ§ λ°νμ§ λ΄μ©μ΄ μκ³ , μ μ²μ± λ¦Όνꡬ μΈν¬μ μνλ³ μ’
μ λ―ΈμΈνκ²½μμμ μν μ λνμ¬ μμ§κΉμ§ μ 립λμ§ μμλ€. λν, μ μ²μ± λ¦Όνꡬ μΈν¬ 3νμ λΉλ‘―ν μ¬λ¬ μ’
λ₯μ λ©΄μ μΈν¬κ° λΆλΉν μ μλ λ¬Όμ§ μ€ νλμΈ μΈν°λ£¨ν¨-17μ΄ μ’
μμ λ―ΈμΉλ μν₯μ λν΄μλ μ°κ΅¬λ§λ€ λ€λ₯Έ κ²°κ³Όλ₯Ό μ μνκ³ μμ΄ μμ§κΉμ§ λ λ§μ μ°κ΅¬κ° νμνλ€. μ΄λ² μ°κ΅¬λ μ μ²μ± λ¦Όνꡬ μΈν¬κ° νμ μ‘°μ§ λ΄μ μ‘΄μ¬ λ° νμ§ μ ν λ°μ μ¬λΆ, μ’
μ λ΄μμμ μν μ νμ
ν΄ λ΄μΌλ‘μ¨ μλ‘μ΄ λ©΄μ μΉλ£ νκ²μ λ°κ΅΄νκ³ μ κ³ννκ² λμλ€.
2015λ
λΆν° 2017λ
κΉμ§ μμΈλνκ΅λ³μμμ λΉμμΈν¬νμμΌλ‘ μ μ μ μ λ°μ νμ 80λͺ
μ μ μ μνμ μ’
μκ³Ό μ μ ν μ‘°μ§μ λμμΌλ‘ κ° μ‘°μ§ λ΄ μ‘΄μ¬νλ λ©΄μ μΈν¬μ λΆν¬ λ° λ°ν λ¬Όμ§μ νμ
νμλ€. λν μ μ μ’
μ μ‘°μ§μμ μ μ²μ± λ¦Όνꡬ μΈν¬λ₯Ό μ»μ λ€ λΉμμΈν¬ νμ μΈν¬μ£Ό νΉμ νμ μ‘°μ§μΌλ‘λΆν° μ»μ μ’
μ μΈν¬μ ν¨κ» λ°°μνμ¬ λνλλ λ³νλ₯Ό νμ
νμκ³ , λ§μ°μ€ μ’
μ λͺ¨λΈμ ꡬμΆνμ¬ μ체 λ΄μμμ μ’
μ μ±μ₯ λ³νλ₯Ό νμΈνμλ€. λν 2001λ
λΆν° 2012λ
κΉμ§ λμΌ κΈ°κ΄μμ λΉμμΈν¬νμμΌλ‘ νμ½ μ μ μ μ μνν νμλ€μ νλΌν λΈλ‘μμ μ’
μ λΆμλ§μ νλνμ¬ μ‘°μ§ λ―ΈμΈλ°°μ΄ λΈλ‘μ μ μ λ° λ©΄μμ‘°μ§νν μΌμμ μννμ¬ μμ μ§νμμ μ°κ΄μ± λ° μμ‘΄ λΆμμ μννμλ€.
μ°μ μ’
μ μΈν¬μμμ μΈν°λ£¨ν¨-17μμ©μ²΄ λ°νκ³Ό μ£Όλ³ λ©΄μ μΈν¬λ€μ μΈν°λ£¨ν¨-17μ λ°νμ μ‘°μ¬νμμ λ μ μμ λΉν΄ νΈνμνΌμΈν¬μμμ λ μΈμ λͺ¨λ λκ² λ°ννκ³ μμμ νμΈνμλ€. μΈν°λ£¨ν¨-17μ λΆλΉν μ μλ μ¬λ¬ λ©΄μ μΈν¬κ΅° μ€μμλ μ μΌνκ² μ μ²μ± λ¦Όνꡬ μΈν¬ 3νμ΄ ν νΈνμνΌμΈν¬μμμ μ μμ΄λ μ μ ν μ‘°μ§μ λΉν΄ λ§μ΄ μ‘΄μ¬ν¨μ κ΄μ°°νμκ³ μ μ²μ± λ¦Όνμ μΈν¬ μνμ λΆν¬λ₯Ό νμ
νμμ λ νΈνμνΌμΈν¬μμμ 3νμ΄ 1νλ³΄λ€ μ’
μ λ΄μ λ§μ΄ λΆν¬νκ³ μμμΌλ μ μμμλ μ μ μ‘°μ§κ³Ό ν° μ°¨μ΄λ₯Ό 보μ΄μ§ μμλ€.
μ΄λ¬ν λΆν¬μ μ°¨μ΄λ μνλ³ μ νμ μ λν μ μλ μ¬μ΄ν μΉ΄μΈ λΆλΉμ μν κ²μ΄λΌλ κ°μ νμ μ¬μ΄ν μΉ΄μΈ λΆλΉμ μ μ²μ± λ¦Όνꡬ μΈν¬ 1ν, 3νκ³Όμ μ°κ΄μ±μ νμΈνμλ€. κ·Έ μ€ μ’
μ μΈν¬μμ λ°νλλ μΈν°λ£¨ν¨-23μ΄ μ μ²μ± λ¦Όνꡬ 1νκ³Ό μμκ΄κ΄κ³λ₯Ό, 3 ν κ³Ό μ μκ΄κ΄κ³λ₯Ό 보μλ€. 곡μλ°°μ μ€νμ νμμ λ νΈνμνΌμΈν¬μ μΈν¬μ μ μ²μ± λ¦Όνꡬ μ 체 νΉμ 1 νμ ν¨κ» λ°°μν κ²½μ°μ 3 ν μ μ¦κ°λ₯Ό 보μκ³ , μ’
μ μΈν¬μ μ¦μ μ¦κ°λ₯Ό νμΈνμλ€. μΆκ°μ μΌλ‘ λ§μ°μ€ λ° λ§μ°μ€ νΈνμνΌμΈν¬μ μΈν¬μ£Όλ₯Ό μ΄μ©νμ¬ μ€νμ νμμ λμλ μΈν°λ£¨ν¨-23 κ³Όλ°ν μ’
μ μΈν¬λ₯Ό ν¬μ¬ν λ§μ°μ€μμ μ’
μ μΈν¬μ μ¦μ μ¦κ° λ° μ μ²μ± λ¦Όνꡬ μΈν¬ 1 ν μ΄ 3 νμΌλ‘ μ νλλ νμκ³Ό μΈν°λ£¨ν¨-17μ μ¦κ°λ₯Ό νμΈνμ¬ μ체 λ΄μμλ κ°μ νμμ 보μμ μ¦λͺ
νμλ€.
λ§μ§λ§μΌλ‘ μ’
μ μ‘°μ§μμ λ©΄μμ‘°μ§ννμΌμμ ν΅ν΄ μ’
μ μΈν¬μμ λΆλΉλλ μΈν°λ£¨ν¨-23μ λ°ν μ¦κ°μ μ μ²μ± λ¦Όνꡬ μΈν¬ 3 ν μ μ¦κ°κ° νΈνμνΌμμμ κ΄μ°°λ¨μ νμΈνμλ€. λν νΈνμνΌμ νμμμλ§ μμ‘΄ λΆμμμ λ μΈμ λͺ¨λ λΆλν μνμ μ°κ΄λ¨μ νμΈν¨μΌλ‘μ¨ μ’
μμ΄ μκ° μμ‘΄ λ° μ±μ₯μ μν΄ μ£Όλ³ λ©΄μμΈν¬, κ·Έ μ€μμλ μ μ²μ± λ¦Όνꡬ μΈν¬μ νμ§ μ νμ μ λν μ μλ λ¬Όμ§μ λΆλΉνμ¬ μκ° μ¦μμ μ΄μ©ν¨μ μ΅μ΄λ‘ λ³΄κ³ νμλ€.
κ²°λ‘ μ μΌλ‘ λ³Έ μ°κ΅¬μλ νΈνμνΌμΈν¬νμμμ λ°ννλ μΈν°λ£¨ν¨-23μ΄ μ’
μ λ΄ λ―ΈμΈνκ²½μ μ‘΄μ¬νλ μ μ²μ± λ¦Όνꡬ μΈν¬ 1 νμ 3 νμΌλ‘ μ νμμΌ μ’
μ λ΄ μΈν°λ£¨ν¨-17 μΆμ μ μ¦κ°λ₯Ό μ λνκ³ , μ΄λ‘ μΈν΄ μΈν°λ£¨ν¨-17 κΈ°μ μ μν μ’
μ μ±μ₯ μ΄μ§μ΄ νμμ λΆλν μνλ‘ μ΄μ΄μ§κ² λλ€λ μ¬μ€μ λ°νλ€.
λ³Έ μ°κ΅¬λ μ μ²μ± λ¦Όνꡬ μΈν¬λ₯Ό μ΄μ©ν μ’
μμ μμ‘΄ μ λ΅μ κ·λͺ
ν¨μΌλ‘μ¨ νμ, κ·Έ μ€μμλ νΈνμνΌμΈν¬μκ³Ό κ°μ΄ μΈν°λ£¨ν¨-23μ λ§μ΄ λΆλΉνλ μ’
μμ λν΄ μΈν°λ£¨ν¨-23/ μ μ²μ± λ¦Όνꡬ μΈν¬ 3/ μΈν°λ£¨ν¨-17 μΆμ ν λΆλΆμ μ°¨λ¨ν¨μΌλ‘μ¨ νμμ μμ‘΄λ₯ ν₯μμ΄ κ°λ₯ν μΉλ£ νκ²μ μ μνλ κ·Όκ±°λ‘ μ¬μ©λ μ μμ κ²μΌλ‘ κΈ°λλλ€.Contents
List of Tables
List of Figures
1. Introduction
1.1 Different two subtypes of non-small cell lung cancer
1.2 Various strategies for tumor survival
1.3 IL-17 pathway in tumor microenvironment
1.4 Innate lymphoid cells and regulation of tumor immunity
2. Materials and Methods
2.1 The cohorts of patients with NSCLC
2.2 Preparation of fresh tissues obtained from NSCLC patients and tissue microarray
2.3 Human and mouse lung cancer cell lines
2.4 Antibodies for immune subset analysis using flow cytometry
2.5 Cell sorting
2.6 Lentiviral transduction and transfection study
2.7 Mice and tumor inoculation in vivo
2.8 Immunohistochemistry
2.9 Immunofluorescence
2.10 Quantitative real-time PCR
2.11 Proliferation assay
2.12 In vitro culture of ILCs
2.13 Co-culture experiments using ILCs
2.14 RNAseq analysis
2.15 TCGA data analysis
2.16 Statistics
3. Results
3.1 The IL-17- IL-17 receptor axis is enhanced in pulmonary SqCCs but not ADCs
3.2 IL-17-IL-17R axis is associated with short survival of SqCC patients
3.3 Higher numbers of ILC3 among IL-17-producing immune cells in SqCCs
3.4 SqCC exhibit an inverse correlation between ILC1 and ILC3 compared to ADCs
3.5 Conversion from ILC1 into ILC3 is promoted by IL-23-producing SqCCs, rather than immune cells, in the TME
3.6 SqCCs rather than ADCs drive the conversion from ILC1 into ILC3 subsets by producing IL-23
3.7 IL-23-producing SqCCs promote tumor growth by inducing ILC3-mediated IL-17 production in in vitro
3.8 IL-23-producing SqCCs promote tumor growth by inducing ILC3-mediated IL-17 production in in vivo
3.9 ILC3 contributes to the poor prognosis of patients with SqCC
4. Discussion
4.1 The conversion of ILC1 into ILC3 by tumor cells exists in TME
4.2 IL-23 mediated novel tumor survival strategy
4.3 IL-23/ILC3/IL-17 axis: a critical pathway of tumor progression in SqCCs
4.4 Conclusive remarks
Bibliography
κ΅λ¬Έμ΄λ‘Docto